|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
First published online 10 January 2007
doi: 10.1242/dev.02765
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Center for Cancer Biology and Nutrition, Institute of Biosciences and
Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd,
Houston, TX 77030-3303, USA.
2 State Key Laboratory of Plant Physiology and Biochemistry, College of
Biological Sciences, China Agricultural University, Beijing 100094, P.R.
China.
3 Center for Advanced Biotechnology and Medicine, UMDNJ-Robert Wood Johnson
Medical School, 679 Hoes Lane, Piscataway, NJ 08854, USA.
4 Department of Molecular Biology and Pharmacology, Washington University,
School of Medicine, 660 South Euclid Avenue, St Louis, MO, 63110, USA.
5 Department of Surgery, University of Western Ontario, London, ON, N6A 4G5,
Canada.
6 Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100
Fairview Avenue, Seattle, WA 98109-1024, USA.
* Author for correspondence (e-mail: fwang{at}ibt.tmc.edu)
Accepted 29 November 2006
| SUMMARY |
|---|
|
|
|---|
Key words: Growth factor, Receptor tyrosine kinase, Androgen dependency, Prostate development, Mouse
| INTRODUCTION |
|---|
|
|
|---|
Adult prostates are androgen-dependent organs with respect to growth,
tissue homeostasis and function. Normally, the epithelium rapidly regresses to
an atrophic state upon depletion of androgens. Approximately 35% of the ductal
tips and branch-points are lost in distal regions within 2 weeks after
orchiectomy. Androgen replenishment induces active cellular proliferation in
the epithelium of atrophied prostate within 2 days, and the epithelial ducts
completely regenerate within 14 days
(Sugimura et al., 1986b
).
Because tissue-recombination experiments showed that the androgen receptor
(AR) in epithelial cells is not essential for prostates to respond to
androgens, it is proposed that paracrinal growth factors between stromal and
epithelial compartments mediate at least some of the regulatory functions of
androgen, and are crucial for androgens to instruct epithelial cells
undergoing proliferation and differentiation
(Cunha, 1996
;
Cunha et al., 2004
;
McKeehan et al., 1998
;
Thomson, 2001
). Reciprocal
communication from epithelia to mesenchyme may also play similar roles in
stroma development, particularly in the differentiation to smooth muscle cells
(Cunha, 1994
;
Cunha et al., 1996
;
Cunha et al., 2004
;
Hayward et al., 1998
;
Jin et al., 2004
). It remains
unresolved whether androgens regulate growth, tissue homeostasis and tissue
functions via similar signaling mechanisms, although the FGF signaling axis
has been implicated to be important for androgen signaling in prostates.
The mammalian FGF family consists of at least 22 gene products that control
a wide spectrum of cellular processes. Most FGFs bind and activate
transmembrane tyrosine kinases receptors (FGFRs) encoded by four highly
conserved genes that exhibit a variety of splice variants
(McKeehan et al., 1998
;
Powers et al., 2000
;
Wang and McKeehan, 2003
).
Expression of FGFs and FGFRs is spatiotemporally-specific in embryos and
tissue- and cell-type-specific in adults. Aberrant activations of FGF
signaling pathways are found in developmental disorders and in diverse
adult-tissue-specific pathologies, including malignant cancer
(McIntosh et al., 2000
;
McKeehan et al., 1998
;
Ornitz, 2000
;
Wang and McKeehan, 2003
).
In prostate, members of the FGF family and alternative splice forms of
FGFRs are partitioned in the epithelium and mesenchyme (stroma), mediating
directional and reciprocal communications between the two compartments.
Ablation of this two-way communication in mature prostates perturbs tissue
homeostasis and leads to prostatic intraepithelial neoplasia (PIN) and
progressively more-severe lesions (Jin et
al., 2003a
; McKeehan et al.,
1998
). In addition, a series of stepwise changes in FGF signaling
contributes to the progression of prostate lesions, including a reduction in
resident FGFR2 expression accompanied by the expression of ectopic epithelial
FGFR1 (Jin et al., 2003a
;
Kwabi-Addo et al., 2001
;
Lu et al., 1999
;
McKeehan et al., 1998
;
Pirtskhalaishvili and Nelson,
2000
). Additionally, changes in the expression of FGF1, FGF2
(Ropiquet et al., 1999
), FGF6
(Ropiquet et al., 2000
), FGF8
(Dorkin et al., 1999
;
Gnanapragasam et al., 2002
;
Song et al., 2002
;
Wang et al., 1999
), FGF9
(Giri et al., 1999b
) and FGF17
(Polnaszek et al., 2004
) have
been observed to be associated with prostatic lesions.
During prostatic organogenesis, messenger mRNAs for both FGF7 and FGF10 are
localized in the mesenchyme, and the receptors for FGF7 or FGF10 are found in
the epithelium of the urogenital sinus in embryos and in the distal signaling
center of elongating and branching ducts in postnatal prostates
(Huang et al., 2005
;
Thomson and Cunha, 1999
). Both
FGF7 and FGF10 can substitute for androgens in organ culture of neonatal
prostates, supporting extensive epithelial growth and ductal-branching
morphogenesis. Ablation of Fgf10 alleles abrogates prostate
development and diminishes androgen responsiveness of prostatic rudiments in
organ-culture and tissue-recombination experiments
(Donjacour et al., 2003
). This
suggests that FGF10 signaling is essential for prostate development. Although
it is generally accepted that the FGFR2IIIb isoform is the primary receptor
for FGF10, the inability of mice deficient in FGFR2 to survive has prevented a
direct analysis of the function of FGFR2 in prostate development, maintenance
of homeostasis and androgen dependency.
To overcome this limitation, we specifically disrupted Fgfr2 alleles in prostate precursor cells at E17.5. Unlike normal prostates, which are composed of two anterior, two dorsal, two lateral and two ventral lobes, most young-adult Fgfr2cn mice developed a small prostate that was frequently limited to two dorsal and two lateral lobes. Development of the epithelial compartment in Fgfr2cn prostates was impaired, which could be characterized by a deficiency in intralumenal infolding. In contrast to wild-type prostates, maintenance of mature Fgfr2cn prostates was not strictly androgen dependent. No significant prostatic atrophy was observed 2 weeks after castration in adult Fgfr2cn mice. Similarly, androgen replenishment to the castrated males also failed to induce cell proliferation in Fgfr2cn prostates. The results showed that FGFR2 signals were essential for strict androgen dependency in adult prostates with respect to tissue homeostasis. Interestingly, as in control prostates, the production of secretory proteins in Fgfr2cn prostates was dramatically reduced by androgen deprivation, suggesting that regulation of the secretory function by androgen remained in these prostates. Together, the data suggest that androgens may elicit regulatory functions in the prostate via multiple pathways. Thus, Fgfr2cn prostates provide a useful animal model for scrutinizing the molecular mechanisms by which androgens regulate prostate growth, homeostasis and function, and may yield clues as to how advanced-tumor prostate cells escape strict androgen regulation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Collection of prostate tissues and histology analysis
The urogenital complex was excised from mice at the indicated ages and
fixed with 4% paraformaldehyde-PBS solution for 30 minutes. The prostates were
then dissected from the urogenital tracks under a stereo microscope, weighted
and further fixed for an additional 4 hours
(Jin et al., 2003a
;
Wang et al., 2004
). In some
cases, when comparisons of individual lobes between mutant and control
prostates were needed, each individual lobe was dissected and fixed
separately. Fixed tissues were serially dehydrated with ethanol, embedded in
paraffin and completely sectioned according to standard procedures.
Immunohistochemical analyses were performed on 7 µm paraffin sections
mounted on Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA). The
antigens were retrieved by autoclaving in Tris-HCl buffer (pH 10.0) for 5
minutes or as suggested by the manufacturers of the antibodies. The source and
concentration of primary antibodies are: mouse anti-cytokeratin 8 (1:15
dilution) from Fitzgerald (Concord, MA); mouse anti-smooth muscle
-actin (1:1 dilution) and mouse anti-PCNA (1:1000 dilution) from Sigma
(St Louis, MO); mouse anti-p63 (1:150 dilution) and mouse anti-AR (1:150
dilution) from Santa Cruz (Santa Cruz, CA); rabbit anti-probasin (1:3000
dilution) from the Greenberg laboratory; and rabbit anti-PSP94 (1:2000
dilution) from the Xuan laboratory. Total numbers of stained cells from a
minimum of three sections per prostate and at least three prostates per
genotype were scored for statistical analyses.
For whole-mount lacZ staining, the urogenital sinuses were lightly fixed
with 0.2% glutaraldehyde for 30 minutes and incubated overnight with 1 mg/ml
X-Gal at room temperature, as described
(Liu et al., 2005
). For TUNEL
assay, tissues were fixed and sectioned as described above, and the apoptotic
cells were detected with the ApopTag Peroxidase In Situ Kit (Chemicon,
Temecula, CA).
Micro-dissections of the prostate were performed according to Sugimura
(Sugimura et al., 1986a
).
Briefly, individual ductal networks of the prostate gland were micro-dissected
after incubation in 1% collagenase-PBS at 4°C overnight. All
micro-dissections were performed under a dissection microscope. Numbers of the
main ducts and distal ductal tips were scored for statistical analyses.
Secreted protein analyses
The urogenital complex was excised from the mice as described above, and
the prostate was dissected from the urogenital complex in PBS. After being
dried with paper towels to remove excessive PBS, the prostate was diced with
scissors in 100 µl PBS containing 1 mM PMDF. The PBS-extracted secretory
proteins were collected by centrifugation as described
(Bhatia-Gaur et al., 1999
). The
protein concentration of the collected sample was normalized with PBS to a
final concentration of 1 mg/ml. Samples equivalent to 25 µg of protein were
separated on a 5-20% gradient SDS PAGE, and the secretory proteins were
visualized with Coomassie Brilliant Blue staining.
In situ hybridization and reverse transcriptase-PCR
For in situ hybridization, paraffin-embedded tissue sections were
rehydrated and digested with protease K for 7 minutes at room temperature.
After prehybridization at 70°C for 2 hours, the hybridization was carried
out by overnight incubation at 70°C with 0.5 µg/ml digoxigenin-labeled
RNA probes specific for the FGFR2IIIB isoform. After being washed four times,
each for 30 minutes, with 0.1xDIG washing buffer at 65°C,
specifically bound probes were detected by the alkaline phosphatase-conjugated
antidigoxigenin antibody (Roche, Indianapolis, IN). For reverse transcriptase
(RT)-PCR analyses, total RNA was extracted from dorsolateral prostates with
the RNeasy Mini Kit (QIAGEN, Valencia, CA). Reverse transcriptions were
carried out with SuperScript II (GIBCO-BRL, Life Technologies, Grand Island,
NY) and random primers according to protocols provided by the manufacturer.
RT-PCR was carried out for 30 and 35 cycles, as indicated, at 94°C for 1
minute, 55°C for 1 minute and 72°C for 1 minute with Taq DNA
Polymerase (Promega, Madison, WI) and specific primers listed in
Table 1. RT-PCR products were
analyzed on 2% agarose gels, and the representing data from at least three
repetitive experiments were shown. Real-time RT-PCR analyses were carried out
with the SYBR Green JumpStart Taq ReadyMix (Sigma) as suggested by the
manufacturer. Relative abundances of mRNA were calculated using the
comparative threshold (CT) cycle method and normalized with ß-actin as an
internal control. Data were the means of three individual experiments.
|
| RESULTS |
|---|
|
|
|---|
Disruption of the Fgfr2 gene in the prostate of 3-week-old males was confirmed by PCR analysis for the absence of the LoxP-flanked exons (Fig. 1C). RT-PCR analyses of prostates in 7-day-old Fgfr2cn mice with FGFR2IIIB-specific primers showed that expression of FGFR2IIIB was below the detection limit; the same experiments with FGFR2IIIC-specific primers or common primers for both FGFR2IIIB and FGFR2IIIC isoforms showed that expression of FGFR2 was significantly reduced in Fgfr2cn prostates (Fig. 1D), indicating that the residual FGFR2 expression was due to expression of the FGFR2IIIC isoform in stromal cells or other minor cell populations. Similar results were derived from 3-week-old prostates (data not shown). Furthermore, in situ hybridization with FGFR2IIIB-specific probes showed that the expression of FGFR2 was diminished in the prostate epithelium at 3 weeks (Fig. 1E). Morphological examination revealed that Fgfr2cn mice had a notably smaller prostate compared with wild-type mice. Only small and thin dp and lp lobes were apparent in the Fgfr2cn prostates, which were also more transparent than control prostates. Because Fgfr2cn dp and lp lobes were small and closely connected, rendering them difficult to separate, the dp and lp lobes were collectively referred to as dlp lobes. Among the 45 Fgfr2cn prostates examined at different ages, 42 exhibited only two dlp lobes. As for the remaining three mice, in addition to two dlp lobes, one mouse also had a very small anterior lobe, one had a ventral lobe, and one had two small anterior and one ventral lobe. Subsequent analyses were mostly performed with the dlp lobes.
Disruption of Fgfr2 alleles in the prostate epithelium inhibited prostatic bud-branching morphogenesis
To visualize better the defects in prostatic development in
Fgfr2cn mice, the ROSA26 reporter allele
(Soriano, 1999
) was bred into
Fgfr2flox/NKX3.1-Cre mice. The disruption of
Fgfr2flox alleles should occur concurrently with
activation of the lacZ reporter by excision of the floxed cassette in ROSA26
alleles. The lower urogenital track was then dissected from embryos and
newborn pups for whole-mount staining with X-Gal
(Fig. 2A). Because the
expression of NKX3.1-Cre is initiated in urogenital sinus epithelial cells
that give rise to prostate epitheliums between E17.0-E17.5 (Y.P.H., S. M.
Price, Z. Chen, W. A. Banach-Petrosky, C. Abate-Shen and M.M.S., unpublished),
X-Gal staining was not visible prior to day E17.0, and was only weakly visible
at E17.25 in a group of cells surrounding the urethra (data not shown). The
staining became more prominent at day E17.5 in cells protruding in different
directions, which represent cells giving rise to the prostatic epithelium
(Fig. 2A). At this stage, both
Fgfr2cn and control embryos developed well-defined ap, dlp
and vp buds; no significant difference in X-Gal-staining patterns was observed
between Fgfr2cn and control animals. At E18.5, the
X-Gal-stained cells in control mice expanded in anterior, dorsolateral and
ventral directions (Fig. 2A).
By contrast, the same cells in Fgfr2cn mice failed to
expand in both anterior and ventral directions, so that the ap and vp buds
remained similar to those in E17.5 embryos. Only the cells in dorsal and
lateral directions expanded and developed into the dp and lp lobes,
respectively. The discrepancy in ap and vp bud formation in
Fgfr2cn and control mice became more significant at
newborn stages. Only the expanding dlp lobes were visible at P5
(Fig. 2A). To further study the
Cre expression pattern, the X-Gal stained tissues were paraffin embedded and
sectioned (Fig. 2A, insert; and
data not shown). The result showed that expression of lacZ was activated
homogenously in the epithelia compartment in every lobe of
Fgfr2cn and control prostate, indicating that NKX3.1-Cre
efficiently and uniformly excised the silencing cassette in the ROSA26 locus
in epithelial cells in every prostatic bud
(Fig. 2A). It is expected that
the floxed Fgfr2 alleles were similarly inactivated in all prostatic
buds at the same time. Thus, the results imply that FGFR2 signals are more
crucial for branching morphogenesis of ap and vp lobes than of dlp lobes,
although the underlying molecular mechanism is not clear.
|
To investigate whether the FGFR2 kinase was required for rapid growth of prostate cells during pubertal development, proliferating cells in Fgfr2cn and control prostates at the ages of 2, 4 and 6 weeks were assessed by the immunostaining of proliferating cell nuclear antigen (PCNA). At pre-pubertal age (2 weeks), the proliferating cells were mainly localized at the distal tips in both Fgfr2cn and control prostates (Fig. 2C). Data from three individual prostates showed that approximately 34.2±5.0% of epithelial cells in Fgfr2cn prostates and 36.2±4.4% in control prostates were actively engaged in proliferation. No significant difference was observed at this stage (P>0.05). At the age of 4 weeks, when the mice were undergoing rapid pubertal growth, the proliferating cells were widely distributed in the whole prostate. At this stage, the population of proliferating cells in Fgfr2cn prostates was significantly smaller than that in control prostates (17.8±1.2% in Fgfr2cn prostate and 35.4±3.5% in control prostate, P<0.01). At the post-pubertal age (6 weeks), the proliferating cell population in both Fgfr2cn and control prostates was dramatically reduced (2.00±0.01% in Fgfr2cn prostate and 2.20±0.05% in control prostate, P>0.05), indicating that both Fgfr2cn and control prostates were mature at this stage. Together, the result demonstrates that ablation of Fgfr2 in prostate epithelium impaired cellular proliferation during pubertal growth.
|
The epithelial compartment of mature prostates mainly consists of
well-differentiated luminal epithelial cells that express cytokeratin 8, and
basal epithelial cells that express p63
(Cunha et al., 2004
;
Kurita et al., 2004
). The
stromal compartment largely consists of smooth muscle cells that express
-actin and are keratin-deficient. To determine whether
Fgfr2cn prostates also express these characteristic
markers, tissue sections were immunochemically analyzed with antibodies
against cytokeratin 8,
-actin and p63. The epithelial and stromal cells
in Fgfr2cn prostates expressed cytokeratin 8 and
-actin, respectively, at levels similar to that seen in control
prostates (Fig. 4A). By
contrast, the population of p63-positive basal cells in
Fgfr2cn prostates was significantly reduced compared with
controls, both in growing and mature prostates
(Fig. 4B,C). To quantitate the
ratio of basal:luminal cells, p63-positive cells in the three sections per
prostate were scored. Data from three individual experiments showed that the
mean ratios of basal:luminal epithelial cells were 0.48 and 0.67
(P<0.001) in 2-week-old, 0.24 and 0.48 (P<0.001) in
4-week-old, and 0.20 and 0.34 (P<0.001) in 6-week-old
Fgfr2cn and control prostates, respectively, which
validated the observation that the basal cells were reduced in
Fgfr2cn prostates.
|
|
|
|
|
Although budding of the prostate is androgen dependent, prostatic ductal
morphogenesis in prenatal and neonatal stages is probably controlled by a
combination of chronic androgen stimulation and an intrinsic `program', which,
because neonatal castration only impairs approximately 60% of prostatic ductal
branching (Donjacour and Cunha,
1988
), is not well-defined. To test whether ablation of FGFR2
signaling altered the androgen dependency of neonatal prostatic morphogenesis,
neonatal castration was performed on Fgfr2cn and control
mice within 24 hours after birth. Results from 2- and 4-week-old neonatally
castrated mice showed that the prostate continued to development in both
Fgfr2cn and control mice, although the size of the dlp
lobes was significantly smaller than that of uncastrated counterparts
(Fig. 8A). Micro-dissection
analyses showed that the differences in complexity of the epithelial ductal
network between Fgfr2cn and control prostates were not
curtailed. Thus, the results indicate that disruption of the FGFR2 signaling
axis in the prostatic epithelium does not diminish androgen dependency for
neonatal branching morphogenesis or for the pubertal growth of prostates.
Together with adult tissue homeostasis data, the result implies divergence in
the control of prostatic branching morphogenesis and growth, and of adult
prostate tissue homeostasis, by androgens.
|
To clarify whether the secretory function of Fgfr2cn prostates is regulated by androgen, prostate secretory proteins were extracted from adult Fgfr2cn and control prostates 2 weeks after castration and were analyzed as above. Results showed that the abundance of total soluble proteins (Fig. 9A), and of probasin and PSP94 (Fig. 9B), were significantly reduced in both Fgfr2cn and control prostates 2 weeks after castration, even though HE staining showed that the lumen of Fgfr2cn prostates was packed with a highly eosinophilic substance. The results suggest that the eosinophilic substances in the prostate of castrated Fgfr2cn mice were not PBS-extractable and, therefore, were not normal prostatic secretory proteins. The results showed that, in both control and Fgfr2cn prostates, the production of probasin and PSP94, as well as other soluble secretory proteins, was controlled by the androgens. Together, the data indicated that, although ablation of the FGFR2 signaling axis in prostatic epithelium diminished androgen activity in the regulation of homeostasis, it did not abrogate androgen activity in the regulation of secretory-protein production in prostates.
| DISCUSSION |
|---|
|
|
|---|
The FGF10-FGFR2 signaling axis is important for prostate branching morphogenesis
The finding that ablation of FGFR2 in prostate epithelia significantly
inhibits prostate branching morphogenesis is consistent with the notion that
FGF10 functions as a mesenchymal paracrine regulator of epithelial growth in
the prostate (Thomson and Cunha,
1999
). However, prostatic phenotypes in
Fgfr2cn mice were generally less severe than in
Fgf10-null mice, because, with a few exceptions that exhibit poorly
developed rudimentary prostatic buds, most Fgf10-null embryos lack
prostatic buds (Donjacour et al.,
2003
). Furthermore, ex-vivo cultures of Fgf10-null
urogenital sinus show that Fgf10-null phenotypes can not be rescued
by FGF10 alone, and can only be partially rescued by FGF10 together with
testosterone, suggesting that FGF10 deficiency may cause other defects as well
as those in the epithelial compartment. Thus, the mechanism underlying
Fgf10-null phenotypes in prostates is not simple. Here, we show that
NKX3.1-Cre only efficiently excised floxed sequences in epithelial cells in
prostatic rudiments in the urogenital sinus; therefore, the defects in
Fgfr2cn prostates were probably direct phenotypes of a
deficiency in FGF10 and/or FGFR2 signals. Thus, Fgfr2cn
prostates provide a good model to assess FGF10 and FGFR2 signaling axis in
prostate development and function.
|
The AR in mesenchymal cells is both essential and sufficient for promoting
epithelial branching morphogenesis and growth during prostate development
(Cunha et al., 2004
). Function
of the epithelial AR is not understood, although it has been reported to be
required for stromal cell differentiation
(Thomson, 2001
). Data from our
present study suggest that the androgen may regulate tissue homeostasis and
the production of secretory protein through different mechanisms; it is also
androgens that regulate the secretory function of epithelial cells directly
through AR signaling pathways within the cells, and that regulate tissue
homeostasis through bidirectional communication between the stromal and
epithelial compartments. The stromal AR-mediated signals for prostate
development and homeostasis have been proposed to be mediated by paracrine
growth factors that have been referred to as andromedins. Although FGF7 and
FGF10 are proposed to be candidate andromedins in rat prostate-tumor models
(Lu et al., 1999
;
Yan et al., 1992
), and
ablation of FGF10 disrupts the development of male secondary sex organs,
including the prostate (Donjacour et al.,
2003
), no evidence shows that the expression of FGF10 is androgen
regulated in normal prostates (Thomson,
2001
; Thomson and Cunha,
1999
). Thus, whether FGF10 functions as an andromedin for prostate
development remains unknown. Although this study did not address the
andromedin issue, the data here demonstrates that FGFR2 signals are important
for prostate to develop into a strictly androgen-dependent organ.
Reduced p63-positive basal cells in the Fgfr2cn prostate
p63-expressing basal cells are a small population of epithelial cells
localized as a discontinuous layer between the luminal epithelial cells and
the basement membrane, and which account for approximately 10% of cells in
mature prostate epithelium. The prostatic basal compartment has been proposed
to consist of a pool of cellular subtypes, including tissue stem cells and
transient/amplifying progenitor cells, which give rise to terminally
differentiated cells (Lam and Reiter,
2006
; Rizzo et al.,
2005
; Tokar et al.,
2005
). However, the cell-lineage relationship between luminal and
basal cells is unclear because the elimination of basal cells by p63 ablation
does not affect neuroendocrine (NE)- and luminal-epithelial cell populations
(Kurita et al., 2004
). Here,
we show that prostate rudiments and growing prostates exhibit a higher ratio
of basal:luminal epithelial cells, the population of which was gradually
reduced as prostates matured (Fig.
4B). Disruption of the FGFR2 signaling axis in prostates
significantly reduced the basal cell population, especially in mature
prostates. FGF7 has been suggested to have a negative effect on the
maintenance of basal cell properties in cell culture by promoting
differentiation (Heer et al.,
2006
). However, our results suggest that FGFR2 signaling is most
probably essential for maintaining basal cell populations in the prostate.
Because NKX3.1-Cre was expressed in both basal and luminal epithelial cells,
it is possible that FGFR2 either directly controls the basal cell population
and their fate-determination within the cells, or indirectly controls this
population through regulatory communications between luminal and basal
epithelial cells. Further efforts are needed to address this issue.
Development of dlp is less dependent on FGFR2 signaling
Experiments with the ROSA26 reporter indicated that NKX3.1-Cre was
expressed in all buds concomitantly between E17.25 and E17.5, indicative that
the Fgfr2 alleles were ablated in all prostatic buds at the same
time. Similar to previous reports (Cunha et
al., 2004
; Thomson,
2001
), data in Fig.
2A show that the buds for each prostatic lobe appeared at E17.5.
No significant difference was noticeable between
Fgfr2cn and control prostates at this stage. The
defects in ap and vp lobe development in Fgfr2cn
mice apparently occurred between E17.5 and E18.5. Together with the notion
that FGFR2IIIB is expressed from the central to the distal tips of the
elongating ducts in every prostatic bud during branching morphogenesis
(Huang et al., 2005
), the
results indicate that the development of ap and vp buds is more FGFR2-signal
dependent than dlp buds, and that the function of FGFR2 in rodent prostates is
lobe-specific. Future experiments with FGFR2IIIB-isoform-null mice will be
carried out to validate this finding. Differential responses to regulatory
signals among the prostatic lobes are not uncommon in rodent. For example,
treating pregnant females with ligands for aryl hydrocarbon receptors also
exhibits a lobe-specific inhibition of prostate branching morphogenesis in
mouse (Ko et al., 2002
); and
ablation of HOXA10 in mice causes partial ap-dlp transformation
(Marker et al., 2001
;
Podlasek et al., 1999
).
It appears that, relative to other prostatic lobes, the dlp has more
potential to escape from strict regulation by the FGFR2 and androgen signaling
axes with respect to growth and tissue homeostasis. With regards to tissue
structure, the dlp in rodents is the most similar to the peripheral zone of
human prostates, where most prostate cancer arises. Together with the fact
that the majority of malignant prostate cancers lose FGFR2 expression and are
not androgen responsive (Giri et al.,
1999a
; Kwabi-Addo et al.,
2001
; McKeehan et al.,
1998
; Wang and McKeehan,
2003
), and that disruption of the FGFR2 signaling axis has been
associated with the progression of prostate lesions in mouse models
(Jin et al., 2003a
;
Polnaszek et al., 2003
), the
results support a model in which the loss of FGFR2 signaling contributes to
the escape from androgen regulation in prostate cancer cells.
Prostate development is orchestrated by multiple signaling pathways,
including SHH, Notch, BMPs and FGFs. FGF10 has been shown to regulate the
expression of multiple morphoregulatory genes, including SHH, BMP4, BMP7,
HOXB13 and NKX3.1 (Huang et al.,
2005
). Here, we demonstrate that, at the mRNA level in
Fgfr2cn prostates, the expression of SHH, BMP7, NKX3.1,
Notch, HOXB13, ß-catenin, Foxa1, FGF7 and FGF10 was similar to that seen
in control prostates; and that of TGF-ß, BMP4 and Hox D13 was reduced.
NKX3.1-Cre mice carry a Cre knock-in allele that is also null for NKX3.1,
which causes slight changes in prostate ductal morphogenesis, as well as in
secretory-protein expression, in ap and vp lobes (Y.P.H., S. M. Price, Z.
Chen, W. A. Banach-Petrosky, C. Abate-Shen and M.M.S., unpublished).
Quantitative RT-PCR results show no significant changes in NKX3.1 expression
in the dlp of Fgfr2cn mice, indicating that the
abnormalities in prostate organogenesis and androgen dependency were
independent of NKX3.1 heterozygosity.
In summary, the FGFR2 tyrosine kinase plays a major role in tissue organogenesis and androgen regulation in prostates. Prostates devoid of epithelial resident FGFR2 responded poorly to androgens with respect to cellular homeostasis. Thus, the results suggest that cross-talk between FGFR2 and androgen signaling axes is important for prostate development, tissue homeostasis and tissue function. These results also provide a hint for how advanced prostate cancer escapes strict regulation by androgens.
Supplementary material
Supplementary material for this article is available at
http://dev.biologists.org/cgi/content/full/134/4/723/DC1
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M.,
Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R.
et al. (1999). Roles for Nkx3.1 in prostate development and
cancer. Genes Dev. 13,966
-977.
Cunha, G. R. (1994). Role of
mesenchymal-epithelial interactions in normal and abnormal development of the
mammary gland and prostate. Cancer
74,1030
-1044.[CrossRef][Medline]
Cunha, G. R. (1996). Growth factors as
mediators of androgen action during male urogenital development.
Prostate Suppl. 6,22
-25.[CrossRef][Medline]
Cunha, G. R., Hayward, S. W., Dahiya, R. and Foster, B. A.
(1996). Smooth muscle-epithelial interactions in normal and
neoplastic prostatic development. Acta Anat. Basel
155, 63-72.[Medline]
Cunha, G. R., Ricke, W., Thomson, A., Marker, P. C., Risbridger,
G., Hayward, S. W., Wang, Y. Z., Donjacour, A. A. and Kurita, T.
(2004). Hormonal, cellular, and molecular regulation of normal
and neoplastic prostatic development. J. Steroid Biochem. Mol.
Biol. 92,221
-236.[CrossRef][Medline]
De Moerlooze, L., Spencer-Dene, B., Revest, J., Hajihosseini,
M., Rosewell, I. and Dickson, C. (2000). An important role
for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in
mesenchymal-epithelial signalling during mouse organogenesis.
Development 127,483
-492.[Abstract]
Donjacour, A. A. and Cunha, G. R. (1988). The
effect of androgen deprivation on branching morphogenesis in the mouse
prostate. Dev. Biol.
128, 1-14.[CrossRef][Medline]
Donjacour, A. A., Thomson, A. A. and Cunha, G. R.
(2003). FGF-10 plays an essential role in the growth of the fetal
prostate. Dev. Biol.
261, 39-54.[CrossRef][Medline]
Dorkin, T. J., Robinson, M. C., Marsh, C., Bjartell, A., Neal,
D. E. and Leung, H. Y. (1999). FGF8 over-expression in
prostate cancer is associated with decreased patient survival and persists in
androgen independent disease. Oncogene
18,2755
-2761.[CrossRef][Medline]
Giri, D., Ropiquet, F. and Ittmann, M. (1999a).
Alterations in expression of basic fibroblast growth factor (FGF) 2 and its
receptor FGFR-1 in human prostate cancer. Clin. Cancer
Res. 5,1063
-1071.
Giri, D., Ropiquet, F. and Ittmann, M. (1999b).
FGF9 is an autocrine and paracrine prostatic growth factor expressed by
prostatic stromal cells. J. Cell. Physiol.
180, 53-60.[CrossRef][Medline]
Gnanapragasam, V. J., Robson, C. N., Neal, D. E. and Leung, H.
Y. (2002). Regulation of FGF8 expression by the androgen
receptor in human prostate cancer. Oncogene
21,5069
-5080.[CrossRef][Medline]
Hayward, S. W., Rosen, M. A. and Cunha, G. R.
(1997). Stromal-epithelial interactions in the normal and
neoplastic prostate. Br. J. Urol.
79 Suppl. 2,18
-26.[Medline]
Hayward, S. W., Haughney, P. C., Rosen, M. A., Greulich, K. M.,
Weier, H. U., Dahiya, R. and Cunha, G. R. (1998).
Interactions between adult human prostatic epithelium and rat urogenital sinus
mesenchyme in a tissue recombination model.
Differentiation 63,131
-140.[CrossRef][Medline]
Heer, R., Collins, A. T., Robson, C. N., Shenton, B. K. and
Leung, H. Y. (2006). KGF suppresses {alpha}2{beta}1 integrin
function and promotes differentiation of the transient amplifying population
in human prostatic epithelium. J. Cell Sci.
119,1416
-1424.
Huang, L., Pu, Y., Alam, S., Birch, L. and Prins, G. S.
(2005). The role of Fgf10 signaling in branching morphogenesis
and gene expression of the rat prostate gland: lobe-specific suppression by
neonatal estrogens. Dev. Biol.
278,396
-414.[CrossRef][Medline]
Huizen, I. V., Wu, G., Moussa, M., Chin, J. L., Fenster, A.,
Lacefield, J. C., Sakai, H., Greenberg, N. M. and Xuan, J. W.
(2005). Establishment of a serum tumor marker for preclinical
trials of mouse prostate cancer models. Clin. Cancer
Res. 11,7911
-7919.
Imasato, Y., Onita, T., Moussa, M., Sakai, H., Chan, F. L.,
Koropatnick, J., Chin, J. L. and Xuan, J. W. (2001). Rodent
PSP94 gene expression is more specific to the dorsolateral prostate and less
sensitive to androgen ablation than probasin.
Endocrinology 142,2138
-2146.
Jin, C., McKeehan, K., Guo, W., Jauma, S., Ittmann, M. M.,
Foster, B., Greenberg, N. M., McKeehan, W. L. and Wang, F.
(2003a). Cooperation between ectopic FGFR1 and depression of
FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse
prostate. Cancer Res.
63,8784
-8790.
Jin, C., McKeehan, K. and Wang, F. (2003b).
Transgenic mouse with high Cre recombinase activity in all prostate lobes,
seminal vesicle, and ductus deferens. Prostate
57,160
-164.[CrossRef][Medline]
Jin, C., Wang, F., Wu, X., Yu, C., Luo, Y. and McKeehan, W.
L. (2004). Directionally specific paracrine communication
mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant
prostate tumors. Cancer Res.
64,4555
-4562.
Johnson, M. A., Hernandez, I., Wei, Y. and Greenberg, N.
(2000). Isolation and characterization of mouse probasin: An
androgen-regulated protein specifically expressed in the differentiated
prostate. Prostate 43,255
-262.[CrossRef][Medline]
Kasper, S. and Matusik, R. J. (2000). Rat
probasin: structure and function of an outlier lipocalin. Biochim.
Biophys. Acta 1482,249
-258.[CrossRef][Medline]
Ko, K., Theobald, H. M. and Peterson, R. E.
(2002). In utero and lactational exposure to
2,3,7,8-tetrachlorodibenzo-p-dioxin in the C57BL/6J mouse prostate:
lobe-specific effects on branching morphogenesis. Toxicol.
Sci. 70,227
-237.
Kurita, T., Medina, R. T., Mills, A. A. and Cunha, G. R.
(2004). Role of p63 and basal cells in the prostate.
Development 131,4955
-4964.
Kwabi-Addo, B., Ropiquet, F., Giri, D. and Ittmann, M.
(2001). Alternative splicing of fibroblast growth factor
receptors in human prostate cancer. Prostate
46,163
-172.[CrossRef][Medline]
Lam, J. S. and Reiter, R. E. (2006). Stem cells
in prostate and prostate cancer development. Urol.
Oncol. 24,131
-140.[Medline]
Lee, D. K. and Chang, C. (2003). Endocrine
mechanisms of disease: expression and degradation of androgen receptor:
mechanism and clinical implication. J. Clin. Endocrinol.
Metab. 88,4043
-4054.
Liu, W., Selever, J., Murali, D., Sun, X., Brugger, S. M., Ma,
L., Schwartz, R. J., Maxson, R., Furuta, Y. and Martin, J. F.
(2005). Threshold-specific requirements for Bmp4 in mandibular
development. Dev. Biol.
283,282
-293.[CrossRef][Medline]
Lu, W., Luo, Y., Kan, M. and McKeehan, W. L.
(1999). Fibroblast growth factor-10. A second candidate stromal
to epithelial cell andromedin in prostate. J. Biol.
Chem. 274,12827
-12834.
Marker, P. C., Stephan, J. P., Lee, J., Bald, L., Mather, J. P.
and Cunha, G. R. (2001). fucosyltransferase1 and H-type
complex carbohydrates modulate epithelial cell proliferation during prostatic
branching morphogenesis. Dev. Biol.
233,95
-108.[CrossRef][Medline]
McIntosh, I., Bellus, G. A. and Jab, E. W.
(2000). The pleiotropic effects of fibroblast growth factor
receptors in mammalian development. Cell Struct.
Funct. 25,85
-96.[CrossRef][Medline]
McKeehan, W. L., Wang, F. and Kan, M. (1998).
The heparan sulfate-fibroblast growth factor family: diversity of structure
and function. Prog. Nucleic Acid Res. Mol. Biol.
59,135
-176.[Medline]
Ornitz, D. M. (2000). FGFs, heparan sulfate and
FGFRs: complex interactions essential for development.
BioEssays 22,108
-112.[CrossRef][Medline]
Pirtskhalaishvili, G. and Nelson, J. B. (2000).
Endothelium-derived factors as paracrine mediators of prostate cancer
progression. Prostate
44, 77-87.[CrossRef][Medline]
Podlasek, C. A., Seo, R. M., Clemens, J. Q., Ma, L., Maas, R. L.
and Bushman, W. (1999). Hoxa-10 deficient male mice exhibit
abnormal development of the accessory sex organs. Dev.
Dyn. 214,1
-12.[CrossRef][Medline]
Polnaszek, N., Kwabi-Addo, B., Peterson, L. E., Ozen, M.,
Greenberg, N. M., Ortega, S., Basilico, C. and Ittmann, M.
(2003). Fibroblast growth factor 2 promotes tumor progression in
an autochthonous mouse model of prostate cancer. Cancer
Res. 63,5754
-5760.
Polnaszek, N., Kwabi-Addo, B., Wang, J. and Ittmann, M.
(2004). FGF17 is an autocrine prostatic epithelial growth factor
and is upregulated in benign prostatic hyperplasia.
Prostate 60,18
-24.[CrossRef][Medline]
Powers, C. J., McLeskey, S. W. and Wellstein, A.
(2000). Fibroblast growth factors, their receptors and signaling.
Endocr. Relat. Cancer 7,165
-197.[Abstract]
Rizzo, S., Attard, G. and Hudson, D. L. (2005).
Prostate epithelial stem cells. Cell Prolif.
38,363
-374.[CrossRef][Medline]
Ropiquet, F., Giri, D., Lamb, D. J. and Ittmann, M.
(1999). FGF7 and FGF2 are increased in benign prostatic
hyperplasia and are associated with increased proliferation. J.
Urol. 162,595
-599.[CrossRef][Medline]
Ropiquet, F., Giri, D., Kwabi-Addo, B., Mansukhani, A. and
Ittmann, M. (2000). Increased expression of fibroblast growth
factor 6 in human prostatic intraepithelial neoplasia and prostate cancer.
Cancer Res. 60,4245
-4250.
Song, Z., Wu, X., Powell, W. C., Cardiff, R. D., Cohen, M. B.,
Tin, R. T., Matusik, R. J., Miller, G. J. and Roy-Burman, P.
(2002). Fibroblast growth factor 8 isoform B overexpression in
prostate epithelium: a new mouse model for prostatic intraepithelial
neoplasia. Cancer Res.
62,5096
-5105.
Soriano, P. (1999). Generalized lacZ expression
with the ROSA26 Cre reporter strain. Nat. Genet.
21, 70-71.[CrossRef][Medline]
Sugimura, Y., Cunha, G. R. and Donjacour, A. A.
(1986a). Morphogenesis of ductal networks in the mouse prostate.
Biol. Reprod. 34,961
-971.[Abstract]
Sugimura, Y., Cunha, G. R. and Donjacour, A. A.
(1986b). Morphological and histological study of
castration-induced degeneration and androgen-induced regeneration in the mouse
prostate. Biol. Reprod.
34,973
-983.[Abstract]
Thomson, A. A. (2001). Role of androgens and
fibroblast growth factors in prostatic development.
Reproduction 121,187
-195.[Abstract]
Thomson, A. A. and Cunha, G. R. (1999).
Prostatic growth and development are regulated by FGF10.
Development 126,3693
-3701.[Abstract]
Tokar, E. J., Ancrile, B. B., Cunha, G. R. and Webber, M. M.
(2005). Stem/progenitor and intermediate cell types and the
origin of human prostate cancer. Differentiation
73,463
-473.[CrossRef][Medline]
Wang, F. and McKeehan, W. L. (2003). The
fibroblast growth factor (FGF) signaling complex. In Handbook of
Cell Signaling. Vol. 1 (ed. R. Bradshaw
and E. Dennis), pp. 265-270. New York:
Academic/Elsevier Press.
Wang, F., McKeehan, K., Yu, C., Ittmann, M. and McKeehan, W.
L. (2004). Chronic activity of ectopic type 1 fibroblast
growth factor receptor tyrosine kinase in prostate epithelium results in
hyperplasia accompanied by intraepithelial neoplasia.
Prostate 58,1
-12.[CrossRef][Medline]
Wang, Q., Stamp, G. W., Powell, S., Abel, P., Laniado, M.,
Mahony, C., Lalani, E. N. and Waxman, J. (1999). Correlation
between androgen receptor expression and FGF8 mRNA levels in patients with
prostate cancer and benign prostatic hypertrophy. J. Clin.
Pathol. 52,29
-34.[Abstract]
Xu, X., Weinstein, M., Li, C., Naski, M., Cohen, R. I., Ornitz,
D. M., Leder, P. and Deng, C. (1998). Fibroblast growth
factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and
FGF10 is essential for limb induction. Development
125,753
-765.[Abstract]
Yan, G., Fukabori, Y., Nikolaropoulos, S., Wang, F. and
McKeehan, W. L. (1992). Heparin-binding keratinocyte growth
factor is a candidate stromal-to-epithelial-cell andromedin. Mol.
Endocrinol. 6,2123
-2128.
Yu, K., Xu, J., Liu, Z., Sosic, D., Shao, J., Olson, E. N.,
Towler, D. A. and Ornitz, D. M. (2003). Conditional
inactivation of FGF receptor 2 reveals an essential role for FGF signaling in
the regulation of osteoblast function and bone growth.
Development 130,3063
-3074.
Related articles in Development:
This article has been cited by other articles:
![]() |
L. M. Cotton, M. K. O'Bryan, and B. T. Hinton Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction Endocr. Rev., April 1, 2008; 29(2): 193 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. McCabe, D. D. Spyropoulos, D. Martin, and C. S. Moreno Genome-Wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer Cancer Res., March 15, 2008; 68(6): 1988 - 1996. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, J. Zhang, Y. Lin, Y. Lan, C. Lin, J. W. Xuan, M. M. Shen, W. L. McKeehan, N. M. Greenberg, and F. Wang Role of epithelial cell fibroblast growth factor receptor substrate 2{alpha} in prostate development, regeneration and tumorigenesis Development, February 15, 2008; 135(4): 775 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hashimoto, M. Taniguchi, S. Yoshino, S. Arai, and K. Sato S Phase-preferential Cre-recombination in Mammalian Cells Revealed by HIV-TAT-PTD-mediated Protein Transduction J. Biochem., January 1, 2008; 143(1): 87 - 95. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||